Evidence map›Paper›PMID 31029144›Full record

ReviewCardiovascular diabetology2019

Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management.

Fei Luo, Avash Das, Jingfei Chen, Panyun Wu, Xiangping Li, Zhenfei Fang

Registry-linked trialOpen access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04930471 (A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability), which is not on this map. Cited by 85 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 7 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04930471 unknown statusnot on this mapstarted 2021, after this paper: background citation

A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2021 to 2023Enrolled45ConditionsAutistic DisorderArmsMetformin
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 7 syntheses or guidelines pooled it, 161 citations in OpenAlex.

  1. Association of metformin use and cancer incidence: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2024 · on this map
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Review
  11. Observational
  12. Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026
    Review
  13. Review
  14. Metformin-loaded J-AuPPS for infected diabetic wound treatment.Frontiers in bioengineering and biotechnology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Fei LuoDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Avash DasDepartments of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Jingfei ChenDepartment of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Panyun WuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Xiangping LiDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. lixp0040@csu.edu.cn.
Zhenfei FangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. fangzhenfei@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CNThe University of Texas Southwestern Medical Center · USXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) is considered an independent risk factor for the development of CAD. Metformin, an anti-diabetic drug, has been shown in pre-clinical and clinical studies, to lower the cardiovascular events in the DM patients. Growing evidence suggests that metformin has a protective effect on coronary artery beyond its hypoglycemic effects. Given its global availability, route of administration and cost, metformin provides an alternate/additional therapeutic option for primary and secondary prevention of CAD in DM and non-diabetics alike. Future prospective cohort-based studies and randomized clinical trials are needed to identify 'at-risk' population who may potentially benefit from metformin.

Indexed as

AnimalsBiomarkersBlood GlucoseCardiovascular AgentsCardiovascular DiseasesClinical Decision-MakingDiabetes MellitusHumansHypoglycemic AgentsMetforminRisk FactorsTreatment OutcomeBiomarkersBlood GlucoseCardiovascular AgentsHypoglycemic AgentsMetforminAtherosclerosisCoronary artery diseaseDiabetes mellitusMetformin

Identifiers

PMID31029144
PMCPMC6486984
OpenAlexW2947600326

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.